You are here

Agency Actions

One of the proposed changes makes remote patient monitoring an allowable cost.
FDA questioning the pharmacokinetics of psoriasis lotion Duobrii
Guidance published on how to best design coverage for treatment of the smallest, most vulnerable victims of the opioid crisis
Agent being studied to combat vulvovaginal candidiasis
Agency aims to ensure women are properly informed of the risks
Agency offers no timeline for addressing PBM-negotiated rebates
Amid delay, teen use of the products has soared to 20%, one plaintiff says
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes
Generic competition pushed back to at least mid-2018
In one case, a required postmarket surveillance study hasn’t even started